Page last updated: 2024-12-07

n,n'-(1,2-dihydroxyethylene)bisacrylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

n,n'-(1,2-dihydroxyethylene)bisacrylamide (DHBA) is a cross-linking agent used in the synthesis of hydrogels. It is a derivative of bisacrylamide, but with two hydroxyl groups attached to the ethylene bridge. These hydroxyl groups contribute to the biocompatibility and hydrophilicity of the resulting hydrogels, making them suitable for applications in biomedical engineering, such as tissue engineering and drug delivery. DHBA is typically synthesized by reacting bisacrylamide with glyoxal in a condensation reaction. The resulting hydrogels exhibit tunable mechanical properties and can be tailored to specific applications by varying the concentration of DHBA and other monomers used in the polymerization process. Due to its biocompatibility, DHBA-based hydrogels have been explored for their potential to mimic the extracellular matrix and provide a suitable environment for cell growth and differentiation. Research on DHBA focuses on understanding the relationship between its chemical structure and the properties of the resulting hydrogels, exploring its applications in various biomedical fields, and developing new strategies to improve its biocompatibility and performance.'

Cross-References

ID SourceID
PubMed CID102501
SCHEMBL ID151457
MeSH IDM0193321

Synonyms (26)

Synonym
2-propenamide, n,n'-(1,2-dihydroxy-1,2-ethanediyl)bis-
AKOS015838882
n,n'-(1,2-dihydroxyethylene)bisacrylamide, 97%
SR-01000641041-1
dheba
868-63-3
n,n'-(1,2-dihydroxyethylene)bisacrylamide
D2864
n,n'-diacryloyl-1,2-dihydroxyethylenediamine
1,2-bisacrylamido-1,2-ethanediol
n-[1,2-dihydroxy-2-(prop-2-enoylamino)ethyl]prop-2-enamide
einecs 212-780-1
ai3-28698
n,n'-(1,2-dihydroxy-1,2-ethanediyl)bis(acrylamide)
n,n'-1,2-dihydroxyethylene-bis(acrylamide)
CCG-51760
FT-0629337
n-[1,2-dihydroxy-2-(prop-2-enamido)ethyl]prop-2-enamide
BP-30078
SCHEMBL151457
mfcd00008624
n,n'-(1,2-dihydroxyethane-1,2-diyl)diacrylamide
DTXSID00862448
F19634
AS-48175
n,n'-(1,2-dihydroxyethylene)bis-acrylamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's1 (9.09)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]